Immunomedics (IMMU) Names Dr. Robert Iannone Head of Research & Development and CMO
Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leader in the field of antibody-drug conjugates (ADCs), today announced the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)